Novotech’s latest white paper 2025 Global Report for In-Vivo CAR Cell Therapy | Novotech CRO is featured in Market Access Today highlighting the rise in vivo CAR-T therapies and their growing role in treating autoimmune diseases.
The article explores how in vivo CAR-T is reshaping clinical development, reducing manufacturing complexity, and expanding access to cell and gene therapies.
With extensive global expertise in early-phase CGT trials and a biotech-focused model, Novotech is recognized as a trusted partner in accelerating innovative programs from preclinical to clinical execution.